

Attorney's Docket No.: 15591-002005 / 470-104US2

RECEIVED  
#7 (42)  
8/3/2  
FILE

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Brugnara et al. Art Unit : 1624  
Serial No.: 10/043,640 Examiner : Unknown  
Filed : January 10, 2002  
Title : SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE  
COMPOUNDS AND ANALOGUES THEREOF USEFUL FOR THE  
TREATMENT OF PREVENTION OF DISEASES CHARACTERIZED  
BY ABNORMAL CELL PROLIFERATION

Commissioner for Patents  
P.O. Box 2327  
Arlington, VA 22202

RECEIVED

JUL 24 2002

TECH CENTER 1600/2900

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Please correct the Filing Receipt for the above-referenced application to correct the name of one of the entities listed in the Assignment for Published Patent Application from Nuchem Pharmaceuticals, Ins. to Nuchem Pharmaceuticals, Inc.

Please supply a corrected Filing Receipt to the undersigned with respect to this application. A copy of the original Filing Receipt showing the desired changes in red ink is attached for your convenience.

No fee is believed to be due. If, however, there are any

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P. O. Box 2327, Arlington, VA 22202.

7/8/02

Date of Deposit

Signature


Debbrah K. Sim

Typed or Printed Name of Person Signing  
Certificate

charges or credits, please apply them to Deposit Account  
No. 06-1050.

Respectfully submitted,

Date: July 8, 2002

  
Mi K. Kim  
Reg. No. 44,830

Fish & Richardson P.C.  
PTO Customer No. 20985  
4350 La Jolla Village Drive, Suite 500  
San Diego, California 92122  
Telephone: (858) 678-5070  
Facsimile: (858) 678-5099  
10196441.doc



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/043,640	01/10/2002	1624	435	13691-002005 / 470-104US2	2	16	3

Gregory P. Einhorn  
Fish & Richardson P.C.  
Suite 500  
4350 La Jolla Village Drive  
San Diego, CA 92122



RECEIVED

JUN 12 2002

FISH & RICHARDSON, P.C.  
SAN DIEGO

CONFIRMATION NO. 7466

UPDATED FILING RECEIPT




\*OC000000008249659\*

Date Mailed: 06/07/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Carlo Brugnara, Newton Highlands, MA;  
Jose Halperin, Brookline, MA;  
Rudolf Fluckiger, Brookline, MA;  
Emile M. Bellott JR., Beverly, MA;  
Richard John Lombardy, Littleton, MA;  
John J. Clifford, Arlington, MA;  
Ying-Duo Gao, Meshanie Station, NJ;  
Reem M. Haidar, Woburn, MA;  
Eugene W. Kelleher, Somerville, MA;  
Adel M. Moussa, Burlington, MA;  
Yesh P. Sachdeva, Concord, MA;  
Minghua Sun, Cambridge, MA;  
Heather N. Taft, Littleton, MA;




## Assignment For Published Patent Application

Children's Medical Center Corporation;  
President and Fellows of Harvard College;  
Nuchem Pharmaceuticals, Inc.;  
Inc.

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/554,849 09/22/2000 ABN  
WHICH IS A 371 OF PCT/US98/24819 11/20/1998  
WHICH CLAIMS BENEFIT OF 08/975,391 11/20/1997



TECH CENTER 1600/2900

**Foreign Applications**

**If Required, Foreign Filing License Granted 02/25/2002**

**Projected Publication Date: 09/12/2002**

**Non-Publication Request: No**

**Early Publication Request: No**

**\*\* SMALL ENTITY \*\***

**Title**

Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).